全文获取类型
收费全文 | 36622篇 |
免费 | 2969篇 |
国内免费 | 2491篇 |
专业分类
耳鼻咽喉 | 298篇 |
儿科学 | 404篇 |
妇产科学 | 350篇 |
基础医学 | 3754篇 |
口腔科学 | 575篇 |
临床医学 | 5417篇 |
内科学 | 4666篇 |
皮肤病学 | 434篇 |
神经病学 | 1494篇 |
特种医学 | 1028篇 |
外国民族医学 | 19篇 |
外科学 | 2945篇 |
综合类 | 7650篇 |
现状与发展 | 6篇 |
一般理论 | 4篇 |
预防医学 | 3061篇 |
眼科学 | 850篇 |
药学 | 4163篇 |
44篇 | |
中国医学 | 2108篇 |
肿瘤学 | 2812篇 |
出版年
2024年 | 108篇 |
2023年 | 472篇 |
2022年 | 1316篇 |
2021年 | 1783篇 |
2020年 | 1445篇 |
2019年 | 1068篇 |
2018年 | 1081篇 |
2017年 | 1118篇 |
2016年 | 996篇 |
2015年 | 1673篇 |
2014年 | 2212篇 |
2013年 | 2148篇 |
2012年 | 3025篇 |
2011年 | 3254篇 |
2010年 | 2447篇 |
2009年 | 1992篇 |
2008年 | 2247篇 |
2007年 | 2270篇 |
2006年 | 2106篇 |
2005年 | 1785篇 |
2004年 | 1100篇 |
2003年 | 1002篇 |
2002年 | 857篇 |
2001年 | 674篇 |
2000年 | 667篇 |
1999年 | 639篇 |
1998年 | 375篇 |
1997年 | 432篇 |
1996年 | 282篇 |
1995年 | 264篇 |
1994年 | 229篇 |
1993年 | 130篇 |
1992年 | 153篇 |
1991年 | 139篇 |
1990年 | 123篇 |
1989年 | 78篇 |
1988年 | 97篇 |
1987年 | 87篇 |
1986年 | 58篇 |
1985年 | 49篇 |
1984年 | 34篇 |
1983年 | 21篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1980年 | 5篇 |
1979年 | 9篇 |
1964年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
大鼠FEZ1基因的克隆及其在中枢神经系统的表达 总被引:1,自引:0,他引:1
轴突成束和延伸蛋白ζ-1(fasciculationandelongationproteinzeta-1,FEZ1),是线虫UNC-76蛋白在哺乳动物中的一种同系物,与轴突向外生长、成束、延伸相关。为了克隆该蛋白的基因并观察其在中枢神经系统(CNS)的表达情况,本研究通过FEZ1的特异引物从SD大鼠脑组织中经逆转录-聚合酶链反应(RT-PCR)获得FEZ1基因;通过RT-PCR法分析FEZ1在生后7d的SD大鼠CNS的不同部位(大脑皮层、嗅球、脊髓)的表达情况。成功获得FEZ1的基因克隆,并观察到生后7d的SD大鼠的大脑皮层、嗅球、脊髓内均有FEZ1表达,且脊髓的表达水平较高。本研究结果为进一步研究大鼠FEZ1基因的生物学活性及在神经系统内的表达和应用奠定了基础。 相似文献
993.
XiaoMin Wan PhD Xia Luo MS ChongQing Tan PhD XiaoHui Zeng PhD YuCong Zhang BS LiuBao Peng BS 《Cancer》2019,125(20):3526-3534
994.
Allison F. O’Neill MD Caihong Xia PhD Mark D. Krailo PhD Furqan Shaikh MD MSc Farzana D. Pashankar MD MRCP Deborah F. Billmire MD Thomas A. Olson MD Jim F. Amatruda MD PhD Doojduen Villaluna MS Li Huang MS Marcio Malogolowkin MD Carlos Rodriguez-Galindo MD A. Lindsay Frazier MD 《Cancer》2019,125(20):3649-3656
995.
996.
Zhixian He Xiaojian Ni Liuwan Xia Zhimin Shao 《Pathology, research and practice》2018,214(10):1648-1654
NIMA Related Kinase 6 (Nek6) is a protein kinase involved in various cellular processes, including cell cycle regulation, apopotosis, senescence, telomere maintainance and chemoresistance. In the present study, we investigated the role of Nek6 in breast tumorigenesis and the prognostic merit of Nek6 expression in breast cancer. Immunohistochemistry and Western blot analyses was conducted to determine the expression profile of Nek6 in 133 breast cancer specimens. Nek6 was overexpressed in a majority of breast cancer specimens, compared with the adjacent non-tumorous tissues. Furthermore, we revealed that high expression of Nek6 was associated with histologic grade, tumor size and TNM stage in breast cancer. Liner regression analysis showed a significant association between the levels of Nek6 and Ki-67. Cox regression analysis indicated that Nek6 expression was an independent prognostic predictor for breast cancer. Moreover, intracellular level of Nek6 was remarkably increased following the release from serum starvation in MCF-7 cells. EdU incorporation assay indicated that depletion of Nek6 remarkably impaired the proliferation of MCF-7 cells. Finally, spheroid formation assay revealed that interference of Nek6 led to diminished oncospheroid-forming capacity of breast cancer cells. In conclusion, our results imply that Nek6 plays a facilitating role in breast cancer cell proliferation and may serve as a promising therapeutic target for breast cancer. 相似文献
997.
998.
目的比较雷贝拉唑两种服药频次对缓解反流性食管炎症状的影响,进一步探讨反流性食管炎的治疗方案。方法 241例胃镜确诊的反流性食管炎患者,随机分为2组,甲组给予雷贝拉唑10 mg每日2次服药,乙组给予雷贝拉唑20 mg每日1次服药。4周后比较各组患者烧心及反流症状的缓解情况。结果甲组121例患者全部有烧心症状,82例有反流症状;乙组120例患者全部有烧心症状,84例有反流症状。治疗后甲组97例患者烧心症状缓解(缓解率80.2%);乙组79例患者烧心症状缓解(缓解率65.8%),2组比较差异有统计学意义(χ2=6.283,P0.05)。甲组70例反流症状缓解(缓解率85.4%);乙组67例反流症状缓解(缓解率79.8%),2组比较差异无统计学意义(χ2=0.904,P0.05)。结论雷贝拉唑10 mg每日2次服药,对烧心症状的缓解优于雷贝拉唑20 mg每日1次服药;2种服药频次对反流症状的疗效无明显差别。 相似文献
999.
De-Li Sun Han-Bing Xie Yun-Zhan Xia 《African journal of traditional, complementary, and alternative medicines》2013,10(6):439-443
The objective of this paper was to study the in vitro anti-breast cancer activity of polysaccharides from Radix ranunculus ternati. Different concentrations of polysaccharide extracts were selected, and MTT assay and flow cytometry (FCM) were used to investigate their growth-inhibitory and apoptosis-inducing effects on human breast cancer MCF-7 cell lines. Radix ranunculus ternati polysaccharides had varying degrees of effects on the growth of human breast cancer MCF-7 cell lines, and the differences were significant compared with the blank control group. FCM showed that the polysaccharides can induce apoptosis. In addition, it can also enhance NK cell activity. Radix ranunculus ternati polysaccharides have a relatively good in-vitro anti-breast cancer activity. 相似文献
1000.
Si-Cheng Liang Guang-Bo Ge Yang-Liu Xia Dong Pei-Pei Wang Ping 《Xenobiotica; the fate of foreign compounds in biological systems》2017,47(6):498-504
1.?Finding and developing inhibitors of catechol-O-methyltransferase (COMT) from natural products is highly recommended. Daphnetin, a naturally occurring catechol from the family thymelaeaceae, has a chemical structure similar to several potent COMT inhibitors reported previously. Here the potential of daphnetin and its Phase II metabolites as inhibitors of COMT was investigated with human liver cytosol (HLC).2.?Daphnetin and its methylated metabolite (8-O-methyldaphnetin) were found to inhibit COMT-mediated dopamine O-methylation in a dose-dependent manner. The IC50 values for daphnetin (0.51~0.53?μM) and 8-O-methyldaphnetin (22.5~24.3?μM) were little affected by changes in HLC concentrations. Further kinetic analysis showed the differences in inhibition type and parameters (Ki) between daphnetin (competitive, 0.37?μM) and 8-O-methyldaphnetin (noncompetitive, 25.7?μM). Other metabolites, including glucuronidated and sulfated species, showed negligible inhibition against COMT. By using in vitro–in vivo extrapolation (IV-IVE), a 24.3-fold increase in the exposure of the COMT substrates was predicted when they are co-administrated with daphnetin.3.?With high COMT-inhibiting activity, daphnetin could serve as a lead compound for the design and development of new COMT inhibitors. Also, much attention should be paid to the clinical impact of combination of daphnetin and herbal preparations containing daphnetin with the drugs primarily cleared by COMT. 相似文献